Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00053846 · ClinicalTrials.gov registry record · Phase 2
Buspirone in Reducing Shortness of Breath in Patients With Cancer
A Phase 2 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 2
- Development phase
- 432
- Enrollment target
NCT00053846 is a Phase 2 study that has completed, run by University of Rochester. The registered enrollment target is 432 participants.
The verdict
NCT00053846, a Phase 2 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 432 participants
- Enrollment target
Study Summary
RATIONALE: Buspirone may be effective in reducing dyspnea (shortness of breath) in patients with cancer who are undergoing chemotherapy. PURPOSE: Randomized clinical trial to study the effectiveness of buspirone in reducing shortness of breath in patients who are undergoing chemotherapy for cancer.
Interventions
- DRUG Placebo
- DRUG buspirone hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 432 participants |
| Start Date | 2002-11 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00053846
The ClinicalTrials.gov registry entry for NCT00053846 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 432 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00053846 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00053846 about?
NCT00053846 is a clinical study titled "Buspirone in Reducing Shortness of Breath in Patients With Cancer". RATIONALE: Buspirone may be effective in reducing dyspnea (shortness of breath) in patients with cancer who are undergoing chemotherapy. PURPOSE: Randomized clinical trial to study the effectiveness of buspirone in reducing shortness of breath in patients who are undergoing chemotherapy for cancer.
What is the current status of trial NCT00053846?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 432 participants. The study started on 2002-11. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00053846?
The interventions under investigation include: Placebo (DRUG), buspirone hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00053846?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.